NCT04389190

Brief Summary

Fluoroscopy is integral part of diagnostic and therapeutic cardiac procedures. Among medical personnel, interventional cardiologists have the highest per head per year exposure to ionizing radiation which is two to three times greater than the radiologists. Although the patients' exposure is well below the level associated with increased cancer risk, yet as mentioned above, any exposure can be harmful and must be minimized using all possible dose reduction methods under the principle of 'As Low as Reasonably Achievable' (ALARA). Radiation exposure is influenced by factors that are dependent on patient (weight, body habitus), procedure (access site, procedure complexity, use of protective shielding, collimation) and equipment (overall quality control, field of view, beam filters thickness, pulse rate etc.). In fact in modern fluoroscopic equipment, several settings are customizable to aid reduce total emitted X-ray dose. In a diverse coronary lab as Tabba Heart institute, in addition to training the lab staff on reducing radiation exposure and use of protective gear, employment of a modern X ray system Like Toshiba (Infinix i8000V, Toshiba America Medical Systems, Inc.); equipped with customizable radiation dose reduction technologies and DTS, provides the interventionists an essential tools to ensure the highest radiation safety standards. Data is still scanty to show the difference in patients and operators' radiation exposures by using tailored equipment settings. We aim to apply customized fluoroscopy protocols based on low fps and other customizable settings (thickness of the spectral beam filters, peak tube voltage and peak cathode current, live zoom (1.4 factors with 12 inch FOV), fluoro store and Spot fluoroscopy) and then assess if they significantly affect the radiation exposure of the patient and the interventionist.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
480

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jul 2020

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 12, 2020

Completed
3 days until next milestone

First Posted

Study publicly available on registry

May 15, 2020

Completed
2 months until next milestone

Study Start

First participant enrolled

July 1, 2020

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2020

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 31, 2021

Completed
Last Updated

May 15, 2020

Status Verified

May 1, 2020

Enrollment Period

6 months

First QC Date

May 12, 2020

Last Update Submit

May 12, 2020

Conditions

Keywords

Radiation exposure, Cardiac cath lab, radiation dose monitoring

Outcome Measures

Primary Outcomes (1)

  • patient and operator radiation exposure

    Operator dose (μSv): Exposure of X-ray to the first and second operator will be measured using the Raysafe i2 system (Unfors Raysafe, Sweden). The personal dosimeter (PDM) in this consists of semiconductors layered with a film and provides real time dose information. All operators will wear the PDM on left side on upper torso. PDM readings will be obtained on an individual procedure basis and readings will be hidden from the operators. Patient total X-ray dose: This will be calculated by obtaining adjusted mean total x-ray dose i.e. air kerma (Gy), dose area product (DAP) (Gy/cm2) and real time Peak skin dose in mGy using Toshiba Inc.'s dose tracking system.

    within 24 hours

Secondary Outcomes (1)

  • quality of imaging

    within 24 hours

Study Arms (3)

Standard Protocol

ACTIVE COMPARATOR

This is the fluoroscopy protocol used routinely in most catheterization labs in the region. This includes fluoroscopy and cine image acquisition at 15 frames per second (FPS) at 8-inch mode. Virtual collimation and last image hold (LIH) will be used as needed. This protocol will be implemented for 6 weeks.

Other: Fluoroscopy settings for image acquisition

Low frame rate protocol

EXPERIMENTAL

This will have fluoroscopy and cine image acquisition at 7.5 FPS at 8-inch mode with all other settings on factory default. Virtual collimation and LIH will be used as needed. This protocol will be implemented for 6 weeks as well.

Other: Fluoroscopy settings for image acquisition

Customized Protocol

EXPERIMENTAL

This will have varying settings based on three weight based groups. Small (\<60 kg), medium (60-85 kg), large (\>85 kg). The variables changed are fluoroscopy dose per frame, fluoroscopy frame rate, image acquisition frame rate, thickness of the spectral beam filters, peak tube voltage and peak cathode current. Additional features will also be utilized including live zoom (1.4 factors with 12 inch field of view, FOV), fluoro store and Spot fluoroscopy. Virtual collimation and LIH will be used as needed. This protocol will be applied for 12 weeks.

Other: Fluoroscopy settings for image acquisition

Interventions

X-ray radiation is routinely used for imaging in coronary cath labs. Intervention involves lowering patient and operators X-ray exposure by employing various setting on the fluoroscopy machine.

Also known as: Fluoroscopy settings on Infinix i8000V, Toshiba America Medical Systems, Inc
Customized ProtocolLow frame rate protocolStandard Protocol

Eligibility Criteria

Age18 Years - 100 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • percutaneous coronary interventional (PCI) and other fluoroscopy assisted cardiac procedures including valvular interventions and device closures.
  • Both emergent and elective procedures.
  • Patients undergoing procedures both via trans-radial or trans-femoral approach will be included.

You may not qualify if:

  • Intra-cardiac device insertions and procedures requiring digital subtraction angiography (DSA) will be excluded.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Tabba Heart Institute

Karachi, Sindh, 75950, Pakistan

Location

MeSH Terms

Conditions

Coronary Artery Disease

Condition Hierarchy (Ancestors)

Coronary DiseaseMyocardial IschemiaHeart DiseasesCardiovascular DiseasesArteriosclerosisArterial Occlusive DiseasesVascular Diseases

Study Officials

  • Asad Z Pathan, MD

    Tabba Heart Institute

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Saba Aijaz, MBBS

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Model Details: This will be a single center non blinded quasi experimental design. Data will be collected prospectively.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 12, 2020

First Posted

May 15, 2020

Study Start

July 1, 2020

Primary Completion

December 31, 2020

Study Completion

March 31, 2021

Last Updated

May 15, 2020

Record last verified: 2020-05

Locations